Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 15.36 -0.45% -0.07
IRWD closed down 0.45 percent on Friday, March 16, 2018, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical IRWD trend table...

Date Alert Name Type % Chg
Mar 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 16 Wide Bands Range Expansion 0.00%
Mar 16 Overbought Stochastic Strength 0.00%
Mar 15 Bearish Engulfing Bearish -0.45%
Mar 15 Stochastic Sell Signal Bearish -0.45%
Mar 15 Outside Day Range Expansion -0.45%
Mar 15 Wide Bands Range Expansion -0.45%
Mar 15 Overbought Stochastic Strength -0.45%
Mar 14 Narrow Range Bar Range Contraction -1.22%
Mar 14 NR7 Range Contraction -1.22%

Older signals for IRWD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 19.94
52 Week Low 12.89
Average Volume 1,632,426
200-Day Moving Average 15.9525
50-Day Moving Average 14.8008
20-Day Moving Average 14.872
10-Day Moving Average 15.072
Average True Range 0.5436
ADX 18.47
+DI 27.63
-DI 15.0
Chandelier Exit (Long, 3 ATRs ) 14.4992
Chandelier Exit (Short, 3 ATRs ) 15.4408
Upper Bollinger Band 15.8409
Lower Bollinger Band 13.9031
Percent B (%b) 0.75
BandWidth 13.029855
MACD Line 0.1982
MACD Signal Line 0.0852
MACD Histogram 0.113
Fundamentals Value
Market Cap 2.3 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -15.67
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.00
Resistance 3 (R3) 16.02 15.83 15.89
Resistance 2 (R2) 15.83 15.66 15.82 15.86
Resistance 1 (R1) 15.59 15.56 15.50 15.57 15.82
Pivot Point 15.40 15.40 15.35 15.39 15.40
Support 1 (S1) 15.17 15.24 15.07 15.15 14.90
Support 2 (S2) 14.98 15.14 14.97 14.86
Support 3 (S3) 14.74 14.98 14.83
Support 4 (S4) 14.72